Oct. 24, 2011
/PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), one of the leading plasma-based biopharmaceutical companies in
the People's Republic of China
, today announced that it has been included in Forbes Magazine's annual list of
's "200 Best Under a Billion" for the year 2011. The Company was also named to the same list for the year 2009.
According to Forbes Asia, Forbes considered only listed companies that have been publicly traded for at least a year and have achieved revenues between
US$ 5 million and $1 billion
The 200 Asia-Pacific companies were selected from more than 15,000 companies, based on their earnings growth, sales growth, and shareholders' return on equity in the past 12 months and over the past three years. For the detailed methodology, please visit
China Biologic was one of the 65 companies in
to make the prestigious list.
Chao Ming Zhao
, the Company's Chief Executive Officer, said, "We are honored that Forbes Magazine has recognized China Biologic as one of the
region's best mid-sized companies for a second time. We believe this accolade reflects our outstanding financial performance, as well as our position as one of the leading plasma-based biopharmaceutical companies in
About China Biologic Products, Inc.
China Biologic Products, Inc., through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co., Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd., and its equity investment in Xi'an Huitian Blood Products Co., Ltd., is one of the leading plasma-based biopharmaceutical companies in
. The Company is a fully integrated biologic products company with plasma collection, production and manufacturing, research and development, and commercial operations. China Biologic's plasma-based biopharmaceutical products are irreplaceable during medical emergencies and are used for the prevention and treatment of various diseases. The Company sells its products to hospitals and other healthcare facilities in
. Please see the Company's website at
for additional information.
Safe harbor statement
This release may contain certain "forward-looking statements" relating to the business of China Biologic Products, Inc. and its subsidiary companies. All statements, other than statements of historical fact included herein are "forward-looking statements," including statements regarding: the ability of the Company to achieve its commercial objectives; the business strategy, plans and objectives of the Company and its subsidiaries; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (
). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
Y. Tristan Kuo
Chief Financial OfficerChina Biologic Products, Inc.Telephone: +86 53 8620 2206Email:
SOURCE China Biologic Products, Inc.